vTv Therapeutics (VTVT) Receivables - Accured (2022 - 2025)

vTv Therapeutics has disclosed Receivables - Accured across 4 years of filings, most recently posting $11.9 million for Q4 2025.

• In Q4 2025, Receivables - Accured changed 0.0% year-over-year to $11.9 million; the TTM figure through Dec 2025 stood at $11.9 million (changed 0.0% YoY), while the FY2025 annual figure was $11.9 million, changed 0.0% from the prior year.
• Receivables - Accured came in at $11.9 million for Q4 2025 at vTv Therapeutics, roughly flat from $11.9 million in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $11.9 million in Q3 2022 to a low of $11.9 million in Q3 2022.
• Average Receivables - Accured over 4 years is $11.9 million, with a median of $11.9 million recorded in 2022.
• The largest YoY upside for Receivables - Accured was 0.0% in 2023 against a maximum downside of 0.0% in 2023.
• Over 4 years, Receivables - Accured stood at $11.9 million in 2022, then changed by 0.0% to $11.9 million in 2023, then changed by 0.0% to $11.9 million in 2024, then changed by 0.0% to $11.9 million in 2025.
• Per Business Quant data, the three most recent Receivables - Accured figures were $11.9 million in Q4 2025, $11.9 million in Q4 2024, and $11.9 million in Q3 2024.